Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613365 | 0.95 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3615612 | 0.88 | LMNA (0.60) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3608848 | 0.86 | RAB9A (0.55) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3597543 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3612174 | 0.82 | RAB9A (0.59) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3602075 | 0.81 | POLB (0.62) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3612236 | 0.81 | RAB9A (0.61) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3614046 | 0.78 | LMNA (0.55) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3612259 | 0.77 | FSCN1 (0.54) | SMN1; SMN2LMNAKDM4EHPGDRAB9A | |
| SCHEMBL3616123 | 0.76 | TP53 (0.57) | SMN1; SMN2LMNAKDM4EHPGDGRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| EP-2132210-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GRM1, GRM2, GRM3 | SMN1; SMN2 1132/4885LMNA 4440/4885KDM4E 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.